Observational Study
Copyright ©The Author(s) 2020.
World J Clin Cases. Jun 26, 2020; 8(12): 2542-2553
Published online Jun 26, 2020. doi: 10.12998/wjcc.v8.i12.2542
Table 1 Comparison of routine detection indicators before and after chemotherapy in the toxic and non-toxic groups
Routine de-tection in-dicatorGroupT0T1T2T3T4Fwithin groupPwithin group valueFbetween groupPbetween group valueFinteractionPinteraction value
LAd (mm)Toxic3.31 ± 0.463.34 ± 0.453.40 ± 0.573.37 ± 0.623.42 ± 0.890.9210.4011.1110.3321.4420.241
Non-toxic3.21 ± 0.883.31 ± 0.693.20 ± 0.823.27 ± 0.923.23 ± 0.87
LVDd (mm)Toxic4.39 ± 0.454.47 ± 0.624.45 ± 0.654.55 ± 0.584.61 ± 0.540.9710.3821.5400.2200.2010.823
Non-toxic4.22 ± 0.634.21 ± 0.734.28 ± 0.894.30 ± 0.844.25 ± 0.93
Mitral valve E/AToxic1.34 ± 0.381.33 ± 0.371.31 ± 0.311.29 ± 0.411.27 ± 0.340.5330.5931.2510.2911.2520.473
Non-toxic1.51 ± 0.511.44 ± 0.461.47 ± 0.521.43 ± 0.461.41 ± 0.51
LVEF (%)Toxic64.92 ± 5.3863.29 ± 6.3963.27 ± 6.8362.36 ± 6.9062.39 ± 5.590.7540.6280.4730.1830.9820.377
Non-toxic65.24 ± 6.4965.37 ± 7.4964.63 ± 6.7263.93 ± 5.8963.28 ± 7.39
ΔLVEF (%)Toxic-0.93 ± 0.311.38 ± 0.381.42 ± 0.332.39 ± 0.480.5520.5791.5830.2110.9420.392
Non-toxic-0.68 ± 0.351.09 ± 0.411.28 ± 0.522.01 ± 0.45
LVFS (%)Toxic37.2 ± 3.437.4 ± 3.336.8 ± 2.936.7 ± 3.636.9 ± 3.10.7640.4721.6220.2030.7400.481
Non-toxic36.8 ± 3.637.1 ± 3.537.4 ± 4.236.4 ± 3.836.5 ± 2.9
E/e'Toxic6.36 ± 1.046.89 ± 1.387.02 ± 1.627.19 ± 1.487.82 ± 1.49a3.9120.0233.1720.0723.9610.022
Non-toxic6.17 ± 1.676.53 ± 1.586.88 ± 1.497.08 ± 1.637.32 ± 1.73
cTnI (μg/L)Toxic0.0231 ± 0.01060.0247 ± 0.01280.0256 ± 0.01930.0289 ± 0.01470.0422 ± 0.0166a5.2010.0072.9740.0844.1230.019
Non-toxic0.0204 ± 0.01480.0226 ± 0.01750.0214 ± 0.01490.0218 ± 0.01280.0228 ± 0.0145
Pro-BNP (ng/L)Toxic94.44 ± 19.3995.92 ± 19.73100.93 ± 21.49112.38 ± 20.38128.68 ± 22.29a5.5730.0053.0630.0824.4520.014
Non-toxic91.29 ± 28.9492.39 ± 31.2994.92 ± 29.3095.93 ± 28.3997.11 ± 30.61
Table 2 Comparison of three-dimensional parameters of the left atrium before and after chemotherapy in the toxic and non-toxic groups
Three-dimen-sional in-dicatorGroupT0T1T2T3T4Fwithin groupPwithin group valueFbetween groupPbetween group valueFinteractionPinteraction value
LAVmin (mL)Toxic14.93 ± 2.0716.93 ± 2.5119.62 ± 2.0721.94 ± 1.91a23.11 ± 2.04a5.2010.0074.5330.01310.0720.000
Non-toxic14.73 ± 3.9215.63 ± 3.2917.39 ± 2.8418.84 ± 2.7217.96 ± 2.28
LAVmax (mL)Toxic34.82 ± 4.9635.11 ± 5.2335.28 ± 5.2836.82 ± 6.0237.72 ± 7.622.9410.0572.5630.0822.7920.066
Non-toxic32.18 ± 5.2933.72 ± 6.2834.13 ± 5.6534.89 ± 5.3935.27 ± 6.39
LAVprep (mL)Toxic23.92 ± 5.2924.29 ± 4.6825.83 ± 5.1727.99 ± 5.53a29.79 ± 4.40a4.7130.0115.0630.0088.3910.000
Non-toxic22.88 ± 4.0223.18 ± 3.7923.69 ± 4.0323.11 ± 4.1822.89 ± 3.03
LAEF (%)Toxic58 ± 858 ± 757 ± 856 ± 856 ± 71.2400.2941.7310.1821.5820.211
Non-toxic60 ± 959 ± 859 ± 958 ± 857 ± 8
Table 3 Multivariate logistic regression analysis of cardiotoxicity in patients with breast cancer after chemotherapy
IndicatorBS.E.WaldP valueOR95%CI
Lower limitUpper limit
T4 E/e'0.2500.2042.1830.1251.2840.8611.915
T4 cTnI0.7330.3175.0240.0252.0811.1183.874
T4 Pro-BNP0.1710.0216.0720.0161.1871.1391.237
T3 LAVmin0.3870.0219.0240.0031.4721.4131.534
T4 LAVmin0.4670.1829.5920.0011.5951.1162.279
T3 LAVprep0.2900.0178.8150.0051.3361.2921.381
T4 LAVprep0.3440.0139.7230.0001.4111.3761.447
Table 4 Receiver operating characteristic curve analysis of potential indicators in predicting the cardiotoxicity after chemotherapy
IndicatorAUC95%CICut off pointSensitivity (%)Specificity (%)
T3LAVmin0.8080.721-0.87820.185.7165.59
T4LAVmin0.9470.886-0.98121.278.5794.62
T3LAVprep0.7530.660- 0.83130.150.0097.85
T4LAVprep0.8990.826-0.94924.410066.67
T4cTnI0.8060.718-0.8760.02492.8656.99
T4Pro-BNP0.7930.704-0.866100.610053.76